iRhythm Technologies (NASDAQ:IRTC) Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC cut its holdings in shares of iRhythm Technologies (NASDAQ:IRTC - Free Report) by 6.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 130,748 shares of the company's stock after selling 8,643 shares during the period. Segall Bryant & Hamill LLC owned about 0.41% of iRhythm Technologies worth $13,687,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Bank Pictet & Cie Europe AG increased its stake in shares of iRhythm Technologies by 5.9% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 3,289 shares of the company's stock worth $297,000 after buying an additional 184 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of iRhythm Technologies by 1.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 259,494 shares of the company's stock worth $23,399,000 after buying an additional 3,791 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of iRhythm Technologies during the fourth quarter worth approximately $9,151,000. PNC Financial Services Group Inc. increased its stake in shares of iRhythm Technologies by 32.3% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,980 shares of the company's stock worth $449,000 after buying an additional 1,215 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of iRhythm Technologies by 15.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,198 shares of the company's stock worth $739,000 after buying an additional 1,068 shares during the period.

Insider Activity at iRhythm Technologies

In related news, CFO Daniel G. Wilson sold 3,000 shares of iRhythm Technologies stock in a transaction on Monday, June 23rd. The shares were sold at an average price of $150.00, for a total value of $450,000.00. Following the transaction, the chief financial officer directly owned 40,307 shares in the company, valued at $6,046,050. This trade represents a 6.93% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Chad Patterson sold 936 shares of iRhythm Technologies stock in a transaction on Monday, June 23rd. The shares were sold at an average price of $150.00, for a total transaction of $140,400.00. Following the completion of the transaction, the insider owned 48,929 shares in the company, valued at approximately $7,339,350. This trade represents a 1.88% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,356 shares of company stock worth $796,882 in the last three months. Insiders own 0.68% of the company's stock.

iRhythm Technologies Stock Performance

Shares of IRTC traded up $0.48 during mid-day trading on Friday, reaching $136.24. 433,891 shares of the company's stock were exchanged, compared to its average volume of 492,646. The company has a debt-to-equity ratio of 7.47, a current ratio of 5.71 and a quick ratio of 5.58. The stock has a market capitalization of $4.35 billion, a PE ratio of -43.39 and a beta of 1.41. The business's fifty day simple moving average is $143.06 and its 200-day simple moving average is $119.47. iRhythm Technologies has a 52-week low of $55.92 and a 52-week high of $157.13.

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.89) by ($0.06). The business had revenue of $158.68 million for the quarter, compared to analysts' expectations of $153.39 million. iRhythm Technologies had a negative return on equity of 101.04% and a negative net margin of 15.90%. The business's revenue was up 20.3% on a year-over-year basis. During the same quarter last year, the business posted ($1.23) earnings per share. On average, equities research analysts expect that iRhythm Technologies will post -1.98 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on IRTC shares. Needham & Company LLC upped their target price on shares of iRhythm Technologies from $138.00 to $151.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Citigroup upped their price target on iRhythm Technologies from $130.00 to $167.00 and gave the company a "buy" rating in a report on Thursday, May 22nd. Wall Street Zen lowered shares of iRhythm Technologies from a "hold" rating to a "sell" rating in a research note on Monday, May 5th. Canaccord Genuity Group dropped their price target on shares of iRhythm Technologies from $152.00 to $139.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Finally, Robert W. Baird increased their price target on shares of iRhythm Technologies from $133.00 to $150.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $137.30.

About iRhythm Technologies

iRhythm Technologies, Inc, a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.